U.S. Medical Equipment Stock News

Lumen Technologies (LUMN) opened Q1 2026 with revenue of US$2.9 billion and a basic EPS loss of US$0.20, alongside net income excluding extra items of a US$200 million loss. Over recent quarters, revenue moved from US$3.3 billion in Q4 2024 to US$3.2 billion in Q1 2025 and US$3.0 billion in Q4 2025. Basic EPS shifted from a profit of US$0.09 in Q4 2024 to losses of US$0.20 in Q1 2025 and US$0.00 in Q4 2025. Taken together, these figures frame Q1 2026 as another period where investors are...

Adaptive Biotechnologies (ADPT) opened Q1 2026 with revenue of US$70.9 million and a basic EPS loss of US$0.13, alongside a net loss of US$20.0 million. Over recent quarters the company has seen revenue move from US$47.5 million in Q4 2024 to US$52.4 million in Q1 2025, US$58.9 million in Q2 2025, US$94.0 million in Q3 2025 and US$71.7 million in Q4 2025. Quarterly EPS ranged from a loss of US$0.23 in Q4 2024 to a profit of US$0.06 in Q3 2025 and back to a loss of US$0.09 in Q4 2025, putting...

The RMR Group Inc. has reported past second-quarter 2026 results, with sales rising to US$5.1 million while revenue fell to US$145.63 million, and quarterly net income declining to US$1.01 million, or US$0.05 per diluted share, compared with the prior year period. Over the first six months of fiscal 2026, higher sales but lower revenue coincided with net income improving to US$13.2 million, highlighting a contrast between weaker quarterly profitability and stronger year‑to‑date earnings. We...

Wondering if Robinhood Markets at around US$79 per share is still compelling value or if the easy gains are behind it? This article breaks down what the current price really reflects. The stock has been volatile recently, with an 11% return over the last 7 days, 13.3% over the last 30 days, a 31.4% decline year to date, and a 58.1% return over the last year, which can shift how the market is thinking about both opportunity and risk. Recent coverage has focused on Robinhood's evolving role in...

What recent moves in Veradermics (MANE) might be telling you Veradermics (MANE) has drawn attention after a sharp month return of about 72% and a very large past 3 months move, putting its clinical stage dermatology pipeline and valuation in sharper focus for investors. See our latest analysis for Veradermics. The recent 72% 30 day share price return and very large 90 day move sit alongside a 190.78% year to date share price return, which points to strong upward momentum despite a 4.38% one...

Investors may be wondering whether United Therapeutics at around US$596.76 is still offering value after a strong run, or if the easy gains are already behind it. The stock has recent returns of 4.5% over 7 days, 6.6% over 30 days, 20.1% year to date, 94.4% over 1 year and 181.2% over 3 years. This puts valuation questions front and center for anyone considering it today. Recent coverage has focused on United Therapeutics as a high growth biotech with a strong pipeline and regulatory...

Pool Corporation (NasdaqGS:POOL) has announced the immediate departure of CEO Peter D. Arvan. John B. Watwood has been appointed as the new President and CEO, with John E. Stokely becoming Executive Chair. The company has postponed its upcoming Investor Day following the leadership change. Pool enters this leadership transition after a period of weak share price performance, with NasdaqGS:POOL at $188.09 and showing a 10.3% decline over the past week and 35.2% decline over the past year...

Centrus Energy (LEU) opened Q1 2026 with revenue of US$76.7 million and basic EPS of US$0.51, against a backdrop of forecast earnings growth of about 7.0% a year and revenue growth around 5.1%. Over recent quarters the company has seen revenue range between US$73.1 million and US$154.5 million with basic EPS between US$0.21 and US$3.21. Trailing 12 month EPS sits at US$3.25 on revenue of US$452.3 million and net income of US$60.6 million, framing a set of results where profit growth and...

In late April 2026, Glaukos Corporation reported first‑quarter 2026 sales of US$150.57 million, a rise from US$106.66 million a year earlier, alongside a net loss of US$19.78 million, and raised its 2026 net sales guidance to a range of US$620 million to US$635 million. At the same time, Glaukos highlighted a broadened ophthalmic portfolio and long-term growth plan, even as insider share sales and continued losses underline ongoing execution and commercialization risks. We’ll now explore how...

Wondering if MKS at around US$293.77 is still offering value after a strong run, or if you might be turning up late to the story. The stock has posted returns of 10.7% over 7 days, 24.0% over 30 days, 74.5% year to date, 298.2% over 1 year and 255.7% over 3 years, with a 5 year return of 83.9%. These moves have kept MKS firmly on investors' radars, as sustained share price strength often raises questions about how the current price lines up with underlying fundamentals. With this context in...

What recent performance signals for Omeros (OMER) Without a single defining headline driving trading, Omeros (OMER) has still drawn attention after a strong month and past 3 months, alongside sizeable 1 year and 3 year total returns. At a recent price of $14.83 and a market cap of about $1.06b, the stock reflects a clinical stage pipeline built around immunologic and rare disease programs rather than current product revenue. See our latest analysis for Omeros. For context, Omeros has paired a...

To figure out whether MP Materials stock still offers value after its strong run, you need to separate a compelling story about rare earths from what the current share price already reflects. The stock last closed at US$72.65, with returns of 18.5% over 7 days, 42.0% over 30 days, 32.2% year to date, 207.6% over 1 year, 221.7% over 3 years and 192.9% over 5 years, so recent performance is front of mind for many investors. Recent news around rare earth supply chains and US focused production...

Wondering whether Academy Sports and Outdoors at around US$54.46 is still priced attractively, or if most of the easy upside is gone? This article focuses squarely on what the numbers say about value. The stock has returned 4.4% year to date and 36.7% over the past year, while the past 30 days and 7 days show declines of 4.8% and 0.7%. This can change how the market is thinking about risk and opportunity. Recent coverage around Academy Sports and Outdoors has centered on how the business is...

ITT (ITT) opened 2026 with Q1 revenue of US$1.2 billion and basic EPS of US$0.89, setting the tone for how the year could unfold against its recent track record. The company has seen quarterly revenue move from US$913 million in Q1 2025 to US$1.2 billion in Q1 2026, while basic EPS ranged from US$1.33 in Q1 2025 to US$1.65 in Q4 2025 before the latest Q1 print. This puts the focus firmly on how much of this top line is flowing through to margins. See our full analysis for ITT. With the latest...

If you are wondering whether Zoetis at around US$111 is a bargain or a value trap, this article will explain what the current price might be implying about the stock. The stock has recently retreated, with returns of 2.3% over 7 days, 6.0% over 30 days, 11.7% year to date, and 27.6% over 1 year. This may have shifted how the market views its risk and reward trade off. Recent coverage has focused on Zoetis as a major animal health company, highlighting how the sector can be influenced by...

Hasbro has signed a long term lease for new creative office space at The Lot at Formosa in West Hollywood. The move expands Hasbro's presence at a historic Hollywood studio campus in the core of the entertainment production district. The new space is intended to support the company’s growing focus on branded entertainment and content related activities. For investors watching NasdaqGS:HAS, the new lease lands at a time when the stock trades at $97.48, with returns of 3.7% over the past...

Coupang (CPNG) opened Q1 2026 with revenue of about US$8.5b and a basic EPS loss of US$0.15, alongside a trailing twelve month basic EPS loss of US$0.09 on revenue of roughly US$35.1b. This keeps the focus firmly on how efficiently that scale is translating into earnings. Over recent quarters the company has seen revenue move from about US$7.9b in Q1 2025 to US$9.3b in Q3 2025 before landing at US$8.5b this quarter. Over the same period, quarterly basic EPS has swung from a profit of US$0.06...

Core Scientific (NasdaqGS:CORZ) has agreed to acquire Polaris DS LLC as part of a plan to expand its Muskogee, Oklahoma data center campus. The Muskogee project is aimed at adding power capacity focused on high-density colocation and AI oriented workloads. This move reflects a greater focus on AI and high-performance computing infrastructure alongside Core Scientific's existing Bitcoin mining operations. Core Scientific, trading at $24.63, has delivered a 25.9% return over the past week and...

Phoenix Asia Holdings (PHOE) has drawn fresh attention after recent trading, with the stock last closing at $28.60. Investors are weighing its substructure construction focus in Hong Kong against recent short term share price moves. See our latest analysis for Phoenix Asia Holdings. The recent 1 day share price return of 39.14% decline contrasts sharply with the 7 day share price return of 83.92% and the year to date share price return of 76.11%. The 1 year total shareholder return is very...

Energy Vault Holdings, Inc. ( NYSE:NRGV ) missed earnings with its latest first-quarter results, disappointing...

A week ago, Rockwell Automation, Inc. ( NYSE:ROK ) came out with a strong set of quarterly numbers that could...

Q1 earnings highlight a narrower loss N-able (NABL) reported first quarter 2026 earnings with a net loss of US$615,000, compared with a net loss of US$7.16 million a year earlier, drawing fresh attention to the stock. See our latest analysis for N-able. The earnings update comes after a mixed share price stretch, with a 10.17% 1 month share price return, a 27.26% year to date share price decline, and a 25.63% 1 year total shareholder return loss, suggesting momentum has been weak despite...

Ouster (OUST) opened 2026 with Q1 revenue of US$48.6 million and a basic EPS loss of US$0.28, alongside a net loss of US$17.5 million. On a trailing 12 month basis, revenue sits at US$185.3 million and basic EPS is a loss of US$0.95 against a net loss of US$55.8 million. Over the past reported quarters, revenue has moved from US$30.1 million in Q4 2024 to US$32.6 million in Q1 2025 and then to US$48.6 million in Q1 2026, with quarterly EPS losses ranging between US$0.48 and US$0.28 across...

If you are wondering whether Solaris Energy Infrastructure is priced fairly after its run, this article focuses on what the current valuation might be telling you about the stock. The share price last closed at US$77.45, with returns of 8.8% over 7 days, 40.4% over 30 days, 54.1% year to date and 259.8% over 1 year, as well as a very large 3 year gain and more than 7x over 5 years. These moves have drawn attention to Solaris Energy Infrastructure, and recent coverage has focused on how the...